Výsledky vyhledávání

Akademický článek

A Mechanistic Site-Of-Action Model: A Tool for Informing Right Target, Right Compound, And Right Dose for Therapeutic Antagonistic Antibody Programs.

Autor: Kapitanov GI; BioMedicine Design, Pfizer Worldwide R&D, Cambridge, MA, United States., Chabot JR; BioMedicine Design, Pfizer Worldwide R&D, Cambridge, MA, United States., Narula J; BioMedicine Design, Pfizer Worldwide R&D, Cambridge, MA, United States., Roy M; BioMedicine Design, Pfizer Worldwide R&D, Cambridge, MA, United States., Neubert H; BioMedicine Design, Pfizer Worldwide R&D, Andover, MA, United States., Palandra J; BioMedicine Design, Pfizer Worldwide R&D, Andover, MA, United States., Farrokhi V; BioMedicine Design, Pfizer Worldwide R&D, Andover, MA, United States., Johnson JS; BioMedicine Design, Pfizer Worldwide R&D, Andover, MA, United States., Webster R; BioMedicine Design, Pfizer Worldwide R&D, Cambridge, MA, United States., Jones HM; BioMedicine Design, Pfizer Worldwide R&D, Cambridge, MA, United States.

Publikováno v: Frontiers in bioinformatics [Front Bioinform] 2021 Sep 03; Vol. 1, pp. 731340. Date of Electronic Publication: 2021 Sep 03 (Print Publication: 2021).

Zobrazit plný text záznamu

Akademický článek

Fc-GDF15 glyco-engineering and receptor binding affinity optimization for body weight regulation.

Autor: Fung E; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Kang L; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Sapashnik D; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Benard S; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Sievers A; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Liu Y; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Yan G; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Zhou J; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Rodriguez L; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Ma W; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA.; Sanofi Research and Development, Sanofi North America, Framingham, MA, USA., Stochaj WR; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., LaVallie E; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Wroblewska L; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Kelleher K; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Tam A; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Bezy O; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA.; Cellarity, Cambridge, MA, USA., Breen D; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Chabot JR; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., He T; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA.; JOINN Biologics US Inc, Richmond, CA, USA., Lin L; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA., Wu Z; Internal Medicine Research Unit, Pfizer Inc., 1 Portland Street, Cambridge, MA, USA., Mosyak L; BioMedicine Design, Pfizer Inc., 610 N Main Street, Cambridge, MA, USA. Lidia.Mosyak@pfizer.com.

Publikováno v: Scientific reports [Sci Rep] 2021 Apr 26; Vol. 11 (1), pp. 8921. Date of Electronic Publication: 2021 Apr 26.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents.

Autor: Londregan AT; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Wei L; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Xiao J; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Lintner NG; Department of Molecular and Cell Biology , University of California, Berkeley , Berkeley , California 94720 , United States., Petersen D; Primary Pharmacology Group, Pharmacokinetics, Dynamics and Metabolism , Pfizer Worldwide Research and Development , Groton , Connecticut 06340 , United States., Dullea RG; Internal Medicine Research Unit , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , United States., McClure KF; Pfizer Medicinal Chemistry, Internal Medicine Research Unit , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , United States., Bolt MW; Drug Safety Research & Development , Pfizer Worldwide Research & Development , Cambridge , Massachusetts 02139 , United States., Warmus JS; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Coffey SB; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Limberakis C; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Genovino J; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Thuma BA; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Hesp KD; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States., Aspnes GE; Pfizer Medicinal Chemistry, Internal Medicine Research Unit , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , United States., Reidich B; Internal Medicine Research Unit , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , United States., Salatto CT; Internal Medicine Research Unit , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , United States., Chabot JR; Pfizer Pharmacokinetics, Dynamics and Metabolism Modeling and Simulation , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , United States., Cate JHD; Department of Molecular and Cell Biology , University of California, Berkeley , Berkeley , California 94720 , United States.; QB3 Institute , University of California, Berkeley , Berkeley , California 94720 , United States.; Department of Chemistry , University of California, Berkeley , Berkeley , California 94720 , United States.; Physical Biosciences Division , Lawrence Berkeley National Laboratory , Berkeley , California 94720 , United States., Liras S; Pfizer Medicinal Chemistry, Internal Medicine Research Unit , Pfizer Worldwide Research and Development , Cambridge , Massachusetts 02139 , United States., Piotrowski DW; Pfizer Medicinal Chemistry , Groton , Connecticut 06340 , United States.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2018 Jul 12; Vol. 61 (13), pp. 5704-5718. Date of Electronic Publication: 2018 Jun 25.

Zobrazit plný text záznamu

Akademický článek

Assessing the Feasibility of Neutralizing Osteopontin with Various Therapeutic Antibody Modalities.

Autor: Farrokhi V; Biomedicine Design, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts, 01810, USA., Chabot JR; Biomedicine Design, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts, 02139, USA., Neubert H; Biomedicine Design, Worldwide Research and Development, Pfizer Inc., Andover, Massachusetts, 01810, USA., Yang Z; Inflammation and Immunology Research Unit, Worldwide Research and Development, Pfizer Inc., Cambridge, Massachusetts, 02139, USA. zhiyong.yang@pfizer.com.

Publikováno v: Scientific reports [Sci Rep] 2018 May 17; Vol. 8 (1), pp. 7781. Date of Electronic Publication: 2018 May 17.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání